Shay Capital LLC Sells 164,457 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Shay Capital LLC reduced its holdings in Chimerix, Inc. (NASDAQ:CMRX) by 71.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,220 shares of the biopharmaceutical company’s stock after selling 164,457 shares during the quarter. Shay Capital LLC’s holdings in Chimerix were worth $227,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Bender Robert & Associates bought a new position in Chimerix in the 4th quarter worth about $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix in the 4th quarter worth about $59,000. Jane Street Group LLC bought a new position in Chimerix in the 4th quarter worth about $62,000. Diadema Partners LP bought a new position in Chimerix in the 4th quarter worth about $101,000. Finally, Stoneridge Investment Partners LLC increased its stake in Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors.

Chimerix Stock Performance

Shares of Chimerix stock opened at $8.54 on Friday. The firm has a market capitalization of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. The business’s 50-day moving average price is $8.52 and its 200-day moving average price is $5.03. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $8.55.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. As a group, analysts predict that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CMRX has been the topic of a number of research analyst reports. HC Wainwright restated a “neutral” rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price objective (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reiterated a “neutral” rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, StockNews.com assumed coverage on Chimerix in a research report on Saturday, May 10th. They set a “sell” rating on the stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.